Buflomedil: One-Year Oral Safety Evaluation in Rats

References

• Dubourg A., Scamulla R. F. An Experimental Overview of a New Vasoactive Drug: Bullomedil HCL. Angiology (1981); 32(10)663
   PubMed Web of Science ®Google Scholar
• Dormandy J. A., Ernst E. Effects of Buflomedil on Erythrocyte Deformability. Angiology (1981); 32(10)714
   PubMed Web of Science ®Google Scholar
• Kushiki K., Ohba M., Midagi T., Nuki S., Araki Y., Furukawa T. Cardiovascular Actions of Buflomedil and Possible Mechanisms Involved. Arzneim.-Forsch./Drug Res. (1989); 39(1)670
   PubMedGoogle Scholar
• Toda N., Okunishi H., Okamura T., Miyazaki M. Effects of Buflomedil on Isolated Dog Arteries, Arch. Int. Pharmacodyn. Ther. (1983); 266: 117
   PubMedGoogle Scholar
• “Drugs Available Abroad”, J. L. Schlesser. Gale Research, Inc., Detroit (1991); 27
   Google Scholar
• Bachand R. T., Dubourg A. Y. A Review of Long-Term Safety Data With Buflomedil. J. Int. Med. Res. (1990); 18(3)245–252
   PubMed Web of Science ®Google Scholar
• Skawinski M. P., Belooussof T., Laisne D., Cazenave-Mahe J. P. Study of Bullomedil in Chronic Arterial Disease of Lower Extremities. Bordeaux Med. (1979); 12: 281
   Google Scholar
• Chermet J. Clinical Pharmacologic Study of the Activity of LL 1656 by Means of Peripheral Adenography. Med. Practic. (1976); 27: 601–610
   Google Scholar
• Roussel J., Oliveux A. Fonzylane in the Treatment of Chronic Arterial Diseases of Lower Extremities. Vie Medicale (1979); 60: 1459
   Google Scholar
• Perrin A. A Clinical Study of Oral Buflomedil in the Treatment of Chronic Arteriopathies of the Lower Limbs. Gaz. Med. Fr. (1977); 84(11)1216
   Google Scholar
• Gournay J. Results of a Double-Blind Clinical Study of Buflomedil in the Treatment of Arteritis of the Lower Limbs, Mises J. Cardiol. (1976); 10: 441
   Google Scholar
• Gay G., Vuillaume C. Buflomedil in the Treatment of Chronic Arteriopathies of the Lower Limbs: Clinical and Functional Study, Ann. Med. Nancy (1977); 16: 1115
   Google Scholar
• Dielz F. Study of Fonzylane in the Treatment of Chronic Arteriopalhies of the Lower Limbs. J. Med. Strasbourg (1978); 9(8)439
   Google Scholar
• Cloarec M. Treatment of Peripheral Circulatory Disturbances: Clinical Study of LL 1656. Vie Medicale (1976); 57(8)427
   Google Scholar
• Desandre M., Couderc J. J. Clinical Study of Fonzylane in Arteriograpny of Lower Limbs. Angeiologie (1980); 32: 278
   Google Scholar
• Balas P., Pagralis N. Experience with Bullomedil in Peripheral Arterial Occlusive Disease. Angiology (1981); 32(10)679
   PubMed Web of Science ®Google Scholar
• Courbier R., Bergeron P., Fouque R. Double-Blind Capillaroscopic Study of the Activity of Buflomedil in Raynaud's Syndrome: A Report of 80 Cases. Angiology (1981); 32(10)676
   PubMed Web of Science ®Google Scholar
• Rosas G., Cerdeyra C., Lucas A. M., Parano R. J., Villa J. J. Comparison of Safety and Efficacy of Buflomedil and Naftidrofuryl in the Treatment of Intermiitent Claudication. Angiology (1981); 32(5)291
   PubMed Web of Science ®Google Scholar
• Baare A., Othoniel J., Mandin A., Dauverchain J. Effect of Buflomedil in Trophic Skin Disorders in the Elderly Subject. Vie Medioale (1981); 62: 85
   Google Scholar
• Genesio M. A.D., Santz M. C. Evaluation of Bullomedii in Geriatric Patients Suffering From Vascular Cerebral Insufficiency. Angiology (1981); 32(10)717
   PubMed Web of Science ®Google Scholar
• Mattera R. The Wechsler-Bellevue Psychometric Test in the Evaluation of the Therapeutic-Effectiveness of Brain Vasoactive Drugs: Buflomedil vs Dihydroergotoxine. El Dia Medico (1980); 52: 455
   Google Scholar
• Espina S. O., Barcena R. P. Action of Vasoactive Drugs on the Symptoms of Chronic Cerebral Vascular Disease: Buflomedil vs Nicergoline. Investigacion Medica Internacional (1981); 8: 392
   Google Scholar
• Silva A. P., de Almeida S. M. L. Bouble Blind Comparative Study of Cinnarizine and Buflomedil in Patients Suffering from Cerebrovascular Insufficience. Angiology (1981); 32(10)728
   PubMed Web of Science ®Google Scholar
• Kobayashi S., Yamaguchi S., Okada K., Kitani M., Yamashita K., Shimote K., Tsunematsu T. Effect of Long-Term Administration of Buflomedil on Regional Cerebral Blood Flow in Chronic Cerebral Infarction. Angiology (1988); 39(11)934
   PubMed Web of Science ®Google Scholar
• Le Quentrec P., Lelebvre L. M. Double-Blind Placebo-Controlled Trial of Buflomedil in the Treatment of Raynaud's Phenomenon: Six-Month Follow-Up. Angiology (1991); 42(4)289
   PubMed Web of Science ®Google Scholar
• Andreozzi G. M., Lepore R. Action and Tolerability of Delayed-Action Buflomedil in Obliterating Arteriopathies of the Lower Limbs A Multicenler Study. Clin. Ter. (1990); 135(4)273
   PubMedGoogle Scholar
• Schmidt J. The Safety and Efficacy of Bufedil (R) Long (Buflomedil 600 mg Delayed Action Tablets) in Patients With Peripheral Arterial Occlusive Disease (Fontaine Stage II a/b). Drug. Invest. (1991); 3/4: 266
   Google Scholar
• Le Devehat C., Vimeux M., Bondoux G., Khodabandehlou T. Effects of Buflomedii on Microvascular Disorders in Diabetic Patients. Blood Vessels (1991); 28: 38, (Suppl. 1)
   PubMedGoogle Scholar
• Trubestein G., Balzer K., Bisler H., Kluken N., Muller-Wiefel H., Unkel B., Mahfoud Y., Ziegler W. Buflomedil in Arterial Occlusive Disease: Results of a Controlled Multicenter Study. Angiology (1984); 35: 500–505
   PubMed Web of Science ®Google Scholar
• Clissold S. P., Lynch S., Sorkin E. M. Buflomedil: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Peripheral and Cerebral Vascular Diseases. Drugs (1987); 33: 430–460
   PubMed Web of Science ®Google Scholar
• Fort F. L., Tekeli S., Lewkowski J. P., Heyman I. A., Cusick P. K., Kesterson J. W. Buflomedil: Three Month Intravenous Safety Eavalualion in Rats. Drug and Chemical Toxicology (1982); 5(4)401
   PubMed Web of Science ®Google Scholar
• Fisher R. A. “Statistical Methods for Research Workers”. Oliver & Boyd, Edinburgh (1950), para. 21.02
   Google Scholar
• Mantel N. Chi-Square Tests With One Degree of Freedom; Extensions of the Mantel-Haenszel Procedure, J. Amer. Statist. Ass. (1963); 58: 690
   Web of Science ®Google Scholar
• Bartlett M. S. Properties of Sufficiency and Statistical Tests, Proc. Roy. Soc. A. (1937); 160: 268
   Google Scholar
• Kruskal W. H., Wallis W. A. Use of Ranks in One-Criterion Variance Analysis, J. Amer. Statist. Ass. (1953); 48: 907
   Web of Science ®Google Scholar
• Gad S., Weil C. S. Hypothesis Testing: Univariate Parametric Tests. “Statistics and Experimental Design for Toxicologists”. The Telford Press. (1986); 70–92
   Google Scholar
• Williams D. A. The Comparison of Several Dose Levels With a Zero Dose Control. Biometrics (1972); 28: 519
   PubMed Web of Science ®Google Scholar
• Shirley E. A Non-Parametric Equivalent of Williams' Test For Contrasting Increasing Dose Levels of a Treatment. Biometrics (1977); 33: 386
   PubMed Web of Science ®Google Scholar
• Burns T. W., Langley P. E. Adrenergic Receptors and Cyclic AMP in the Regulation of Human Adipose Tissue Lipolysis. Annals of the New York Academy of Sciences (1971); 185: 115
   PubMed Web of Science ®Google Scholar
• Zahorska-Markiewicz B., Kucio C., Piskorska D. Adrenergic Control of Lipolysis and Metabolic Responses in Obesity, Horm. Metabol. Res. (1986); 18: 693
   PubMed Web of Science ®Google Scholar
• Comai K., Sullivan A. C. Effect of Phenoxybenzamine on Development of Adipose Tissue in Lean and Obese Zucker Rats. Am. J. Physiol. (1982); 243: E398, (Endocrinol. Metab. 6)
   PubMed Web of Science ®Google Scholar